Archives Press Releases

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that investors can now subscribe to the 2025/29 corporate bond (ISIN: NO0013586024 / WKN: A4DFJH) via Deutsche Börse’s ‘DirectPlace’ subscription service. This service allows interested investors to place purchase orders directly with their house bank or custodian bank on the Frankfurt Stock Exchange during the subscription period. Since June 17, 2025, it is also possible to subscribe to the bond directly via the company website at (https://www.formycon.com/en/investor-relations/bond-2025/). The company intends to use the proceeds to advance its growth strategy – in particular for the consequent development and expansion of the Company’s biosimilar product portfolio.

“With this bond, we are opening ourselves up to a broader investor base and are utilizing the bond market as a strategic capital market instrument for the first time. This gives us the flexibility to further develop our pipeline and strengthen our position as a growth-oriented company with an increasing commercial focus,” explains Enno Spillner, CFO of Formycon AG.

The bond governed by Norwegian law, is intended to be included in the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. Additionally, the Company intends to apply for the bond to be admitted to trading on Euronext ABM, a self-regulated marketplace operated by the Oslo Stock Exchange (Oslo Børs), within six (6) months following issuance.

The transaction is being led by IKB Deutsche Industriebank AG and Pareto Securities AS as Joint Lead Managers. The bonds are being issued as part of a public offering in Luxembourg, Germany and Austria. The offering is based on a securities prospectus approved by CSSF, which has been notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The prospectus is available on the websites of the Luxembourg Stock Exchange (www.luxse.com) and Formycon AG (https://www.formycon.com/en/investor-relations/bond-2025/).

In addition, the Joint Lead Managers plan to offer the bond to institutional investors in Germany, Luxembourg, and Austria, as well as selected other European and international markets as part of a private placement.

Key Terms of the Formycon Corporate Bond 2025/2029

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) announces that the securities prospectus for the newly issued corporate bond 2025/2029 (ISIN NO0013586024 / WKN A4DFJH) has been approved by the Luxembourg financial supervisory authority (CSSF) on June 17, 2025, and that investors can now subscribe to the bond via the company’s website. The newly issued four-year unsecured senior bond has a target volume of EUR 50 million and carries a variable interest rate.

The Management and Supervisory Boards of Formycon AG approved the new bond issuance on June 17, 2025. The proceeds will be used to advance Formycon’s growth strategy – in particular for the consequent development and expansion of the Company’s biosimilar product portfolio. The bond has a minimum subscription amount of EUR 1,000, is governed by Norwegian law and carries a variable interest rate consisting of three-month EURIBOR plus a margin between 7.0% and 7.5% p.a. The final margin is expected to be determined and announced on June 30, 2025, based on submitted subscription offers.

Interested investors can submit binding subscription offers during the subscription period either via the company’s website (www.formycon.com; subscription period: June 18 to June 27, 2025, 11:59 p.m. CEST) or via Deutsche Börse’s “DirectPlace” subscription functionality (subscription period: June 20 to June 30, 2025, 12:00 noon CEST), subject to early closing. Using DirectPlace, investors can place buy orders through their custodian bank during the subscription period at the Frankfurt Stock Exchange; alternatively, subscription via the company’s website is available.

The Bond, governed by Norwegian law, is intended to be included in the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. Additionally, the Company intends to apply for the Bond to be admitted to trading on Euronext ABM, a self-regulated marketplace operated by the Oslo Stock Exchange (Oslo Børs), within six (6) months following issuance.

The transaction is being led by IKB Deutsche Industriebank AG and Pareto Securities AS as Joint Lead Managers. The bond was issued as part of a public offering in Luxembourg, Germany, and Austria. The offering is based on a securities prospectus approved by CSSF, which has been notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The prospectus is available on the websites of the Luxembourg Stock Exchange (www.luxse.com) and Formycon AG (www.formycon.com, section ‘Investor Relations’).

In addition, the Joint Lead Managers plan to offer the bond to institutional investors in Germany, Luxembourg, and Austria, as well as selected other European and international markets as part of a private placement.

With the placement of the bond, Formycon is utilizing this capital market instrument for the first time to further and sustainably strengthen its position as a growth-oriented company with an increasing commercial focus in a highly attractive and dynamically growing market.

Key Terms of the Formycon Corporate Bond 2025/2029

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) today decided to issue a four-year corporate bond (ISIN NO0013586024 / WKN A4DFJH) with a target volume of EUR 50 million. The company intends to use the proceeds to advance its growth strategy – in particular for the consequent development and expansion of the Company’s biosimilar product portfolio.

“In recent years, Formycon has evolved from a biosimilar development company into a commercially focused company with a growing and maturing product portfolio while increasing revenues from global licensing and commercialization partnerships. This commercial foundation enables us to tap into another attractive source of financing with the planned bond issuance. It is our goal to transition our corporate financing towards a more long-term setup. In doing so, we are optimizing our capital structure and tapping into debt capital for the first time. The proceeds will support the continued execution of our strong growth strategy, the optimization of our biosimilar platform, and the further strengthening of our position as a commercially operating company. Having laid a solid groundwork with the necessary structures and processes over the past years, we are now ready to scale them to the next success level,” said Enno Spillner, CFO of Formycon AG.

The transaction is being led by IKB Deutsche Industriebank AG and Pareto Securities AS as Joint Lead Managers. The bonds will be issued as part of a public offering in Luxembourg, Germany, and Austria. The offering is based on a securities prospectus which is expected to be approved today by the Luxembourg financial supervisory authority (CSSF) and to be notified to the German Federal Financial Supervisory Authority (BaFin) and the Austrian Financial Market Authority (FMA). The prospectus will be published on the websites of the Luxembourg Stock Exchange (www.luxse.com) and Formycon AG (www.formycon.com, section ‘Investor Relations’).

In addition, the Joint Lead Managers plan to offer the bond to institutional investors in Germany, Luxembourg, and Austria, as well as selected other European and international markets as part of a private placement.

Interested investors may submit their binding subscription offers during the offering period either through Deutsche Börse’s subscription functionality “DirectPlace” (subscription period: June 20 to June 30, 2025, 12:00 p.m. CEST) or via the Formycon AG website (www.formycon.com; subscription period: June 18 to June 27, 2025, 11:59 p.m. CEST), subject to an early closing of the subscription period. When using DirectPlace, investors may place purchase orders through their house or custodian bank on the Frankfurt Stock Exchange during the subscription period; alternatively, the subscription is also possible via the website.

The Bond, governed by Norwegian law, will have a term of four years. The minimum investment amount is EUR 1,000. The interest rate will be based on the three-month EURIBOR plus a margin ranging from 7.0% to 7.5% per annum. The final margin and total nominal amount of the Bond are expected to be determined and announced on or around June 30, 2025, based on the subscription offers received.

The Bond is intended to be included in the Open Market (Freiverkehr) of the Frankfurt Stock Exchange. Additionally, the Company intends to apply for the Bond to be admitted to trading on Euronext ABM, a self-regulated marketplace operated by the Oslo Stock Exchange (Oslo Børs), within six (6) months following issuance.

With the placement of the bond, Formycon is utilizing this capital market instrument for the first time to further and sustainably strengthen its position as a growth-oriented company with an increasing commercial focus in a highly attractive and dynamically growing market.

Key Terms of the Formycon Corporate Bond 2025/2029

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) today announces that the Brazilian regulatory authority ANVISA has granted marketing authorization for Ranivisio^®1, a biosimilar to Lucentis^®2 (ranibizumab). Product launch by the Brazilian biopharma specialist Biomm is expected in Q4 2025, marking the beginning of a phased market rollout of FYB201/Raniviso^® across Latin America. Marketing authorizations have already been granted by the regional regulatory authorities in Peru, El Salvador, Honduras, and the Dominican Republic. Further approvals and product launches in Central and South America are planned through early 2027.

“The marketing approval of FYB201/Ranivisio^® in Brazil underlines our mission to improve access to high-quality biologic drug therapies especially in countries where the usage of high-cost biologics is quite limited today,” says Formycon CBO Nicola Mikulcik, adding: “We are extremely pleased to offer a safe, effective and affordable treatment option for the growing patient population with severe retinal diseases in Brazil. In Biomm, we have a strong commercial partner with in-depth knowledge of the local market and the specific requirements of the ophthalmology sector. Based on the country-by-country rollout in LATAM, which is planned to start in Q4 this year, we expect the region to become a good contributor to our profits mid-term.”

Biomm is a well-established pharmaceutical company with a strong presence in Brazil, the largest healthcare market in South America. The company focuses on the development, manufacturing and distribution of biopharmaceutical drugs, including biosimilars. According to Biomm, the Brazilian market for anti-VEGF therapies, including the active ingredient ranibizumab, is valued at BRL 374 million (approx. US$ 66 million) annually and has demonstrated consistent growth over the past three years.

FYB201/Ranivisio^® (ranibizumab) is used to treat severe visual impairments such as wet age-related macular degeneration (nAMD) and other retinopathies. Developed by Bioeq AG, a joint venture between Formycon AG and Polpharma Biologics Group BV, the biosimilar is currently available in a total of 21 countries in Europe, North America and the MENA region.

¹Ranivisio^® is a registered trademark of Bioeq
²Lucentis^® is a registered trademark of Genentech Inc.

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) and its commercialization partner Fresenius Kabi proudly announce the market launch of FYB202/Otulfi^™1 an ustekinumab biosimilar referencing Stelara^®2 in Canada. Following Health Canada’s Notice of Compliance (NOC) end of December 2024, Otulfi^™ is now available as a high-quality and cost-effective treatment option for adult patients with moderate to severe active Crohn’s disease, moderate to severe active ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis.

“Canada is a key market with a strong commitment to biosimilar adoption. We are proud that our ustekinumab biosimilar is now available to Canadian patients, contributing to broader access to high-quality biologic therapies across the North American continent,” said Dr. Stefan Glombitza, CEO of Formycon AG. “For many patients suffering from chronic inflammatory diseases, access to biologic therapies remain limited. There are often substantial delays that keep patients from benefiting from these highly effective treatments when they need them most. Biosimilars like Otulfi^™ play a crucial role in reducing healthcare expenditure while maintaining high standards in quality and safety of patient care.”

To support patients transitioning to Otulfi^™, Fresenius Kabi provides access to its KabiCare^® patient support program. KabiCare^® offers a full range of services including injection training, reimbursement assistance, a dedicated single point of contact, bloodwork coordination and lifestyle assessments. With KabiCare^®, patients receive assistance in accessing their medicine, ongoing support, education, and guidance throughout their biosimilar treatment journey.

“The high demand for biosimilars in Canada underscores the necessity for accessible and cost-effective biologics. We are very proud to be introducing a cost-effective and European manufactured alternative ustekinumab treatment for patients living with inflammatory and immune diseases,” said Abhi Bhoite, Sr. Director and Head of Commercial, Fresenius Kabi Biopharma, Canada.

Ustekinumab is a human monoclonal antibody that targets the cytokines interleukin-12 and interleukin-23 which play an important role in inflammatory and immune responses. Otulfi^™ was approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in September 2024 and launched in Europe and the U.S. in March 2025.

Otulfi^™ is available in Canada in the following presentations:

• 45 mg/0.5 mL and 90 mg/mL single-dose prefilled syringe for subcutaneous injection
• 130 mg/26 mL (5 mg/mL) single dose vial for IV infusion.

¹⁾ Otulfi^™ is a trademark of Fresenius Kabi Deutschland GmbH in selected countries
²⁾ Stelara^® is a registered trademark of Johnson & Johnson

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its commercialization partner Fresenius Kabi announce today that the U.S. Food and Drug Administration (FDA) designated FYB202/Otulfi^®1 (ustekinumab-aauz) as interchangeable with the reference biologic Stelara^®2 (ustekinumab). As of April 30, 2025, Otulfi^® is interchangeable in all presentations matching the reference product.

Fresenius Kabi launched the 45 mg and 90 mg single-dose prefilled syringe for injection as well as the 130 mg single dose vial presentations for IV infusion in the U.S. beginning of March 2025. In April the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code (Q-Code) for Otulfi^®. These codes are used by commercial insurers and government payers to standardize claims submissions and simplify reimbursements.

Dr. Stefan Glombitza, CEO of Formycon AG, commented: “The interchangeability designation for FYB202/Otulfi^® in the U.S. is a strong endorsement of the product’s excellent quality and underscores Formycon’s recognition as one of the leading biosimilar developers. Both the product-specific reimbursement code and the interchangeability designation are important drivers of improved patient access to a much-needed treatment option for severe inflammatory diseases in the U.S. This will create additional impetus for market uptake.”

Depending on state pharmacy laws in the U.S., an interchangeable biosimilar can be dispensed at the pharmacy as a substitute for the reference product without requiring direct approval from the prescribing healthcare provider. Not all biosimilars receive interchangeability status.

FYB202/Otulfi^® was approved by the U.S. Food and Drug Administration (FDA) in September 2024 for the treatment of the same conditions as Stelara^®. FDA approval and interchangeability designation are based on a thorough evaluation of a comprehensive data package including analytical, pre-clinical, clinical and manufacturing data. FYB202/Otulfi^® demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to the reference drug in patients with moderate to severe plaque psoriasis and offers a comprehensive, alternative treatment solution for health care professionals and patients treated with ustekinumab in the U.S.

¹⁾ Otulfi^® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
²⁾ Stelara^® is a registered trademark of Johnson & Johnson

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, Prime Standard, “Formycon”) today reports on the Group’s business development and financial results for the first quarter of fiscal year 2025. The reporting period was marked by operational milestones and positive regulatory trends, successful product launches, the expansion of international commercialization partnerships but also by challenging macroeconomic conditions.

Dr. Stefan Glombitza, CEO of Formycon AG, stated: “Q1 was a turbulent quarter for our industry and Formycon alike. Nevertheless, we achieved several important milestones during the reporting period. These include, in particular, the successful market launch of our Stelara^®2 biosimilar FYB202/Otulfi^® in the U.S. and Europe, as well as the approval of our Eylea^®3 biosimilar FYB203 in Europe and the United Kingdom. Just a few weeks after launch, FYB202 already generated notable revenue contributions. This encouraging start, against the backdrop of increasing biosimilar penetration, confirms the product’s international market potential. We remain firmly focused on the strategic advancement of our pipeline and are particularly well positioned with our Keytruda^®4 biosimilar FYB206 to drive further growth.”

Enno Spillner, CFO of Formycon AG, added: “With our pioneering development strategy for FYB206, we are significantly reducing development costs while reinforcing our leading role in the global competition for a biosimilar to Keytruda^®. Despite increasing economic challenges in the U.S. market, we are operating well within our communicated financial guidance. Even in light of volatile capital markets and macroeconomic uncertainties, including U.S. trade policy, Formycon remains strategically and operationally on track. We reaffirm our guidance for the current fiscal year and remain committed to achieving sustainable, EBITDA-positive growth.”

Strong start to the year marked by key operational achievements

In January 2025, FYB203 (Aflibercept), a biosimilar to Eylea^®, was approved by the European Commission under the brand names AHZANTIVE^®5 and Baiama^®6. UK approval followed in February. Teva Pharmaceuticals will market FYB203 on a semi-exclusive basis across major parts of Europe. In addition, Formycon entered into a commercialization agreement with Lotus Pharmaceutical for the Asia-Pacific region.

Formycon’s commercialization partner Fresenius Kabi initiated the U.S. launch of FYB202 (ustekinumab), a biosimilar to Stelara^®, at the end of February with an encouraging start. Shortly thereafter, the European launch followed in early March. In the meantime, FYB202 also received important marketing authorizations in the United Kingdom and Canada. To further expand its global presence and maximize commercial potential, Formycon also initiated a partnership with MS Pharma for the MENA region. After the reporting period, FYB202/Otulfi^® was assigned a permanent, product-specific reimbursement code (Q-code) in the U.S., facilitating reimbursement by private and public payers.

Based on the positive feedback from the U.S. Food and Drug Administration (FDA), Formycon decided to waive the Phase III trial with FYB206 (Pembrolizumab) in February 2025 as the therapeutic comparability of FYB206 with the reference medicine Keytruda^® can be sufficiently demonstrated based on comprehensive analytical data and data from the ongoing Phase I study. The Phase I trial in malignant melanoma continues as planned. This decision accelerates development of the biosimilar and reduces the investments over the coming years by more than €75 million. In a recently published “reflection paper”⁷, the European Medicines Agency (EMA) has also signaled its support for this approach, reinforcing Formycon’s position as a pioneer among pembrolizumab biosimilar developers.

FYB201 (ranibizumab biosimilar) is available in 20 countries worldwide and has continued to strengthen its position in various markets. Competitive discounting by ranibizumab providers in the U.S. prompted Formycon’s commercialization partner Sandoz AG to adjust its marketing strategy and to implement a temporary pause in the commercialization of FYB201/Cimerli^®8 for approximately one year, starting at the end of Q1 2025. Following the pause, the product is to be strategically repositioned to target new customer segments. The product remains available in other regions, including Europe and MENA, where it is marketed by Teva and MS Pharma, respectively. With the planned launch of the pre-filled syringe in 2025, further market penetration is expected, particularly in Europe. Further markets such as in Latin America are targeted for expansion.

Alongside its advanced biosimilar programs, Formycon continues to drive the development of new pipeline candidates. The candidates FYB208, FYB209, and FYB210 are currently in early stages of development. FYB208 is expected to enter the clinical phase later this year upon achieving Technical Proof of Similarity.

Following Formycon’s successful inclusion in the SDAX at the end of 2024, the company’s visibility as one of Germany’s key technology stocks was further enhanced at the beginning of 2025 through its admission to the TecDAX.

Group revenue and EBITDA in line with expectations – FYB202 revenue contributions reflect a successful market launch

Formycon Group generated revenues of €5.3 million in Q1 2025 (Q1/2024: €17.7 million). The year-on-year decline was anticipated and reflects the revenue mix shift. In the prior-year period, significant milestone revenues were recognized from the commercialization partnership with Fresenius Kabi related to the FYB202 project. As development of the pre-filled syringe for the two ophthalmic biosimilars FYB201 and FYB203 progressed successfully, revenues from reimbursed development services declined as expected accordingly.

Despite being on the market for only about one month in the U.S. and Europe, FYB202/Otulfi^® generated revenues of €0.74 million in the first quarter, demonstrating a positive market launch. Further increasing revenue contributions are expected over the course of the year, positioning FYB202 as a key revenue driver for the Group in 2025.

As expected, revenues from the ranibizumab biosimilar FYB201 were below the prior-year level. This was attributable to continued price pressure and the previously announced temporary pause in U.S. commercialization by partner Sandoz, which took effect on April 1, 2025. Direct revenue contributions from commercialization of the Lucentis^®9 biosimilar FYB201 amounted to €0.6 million (Q1/2024: €1.9 million). A further significant portion of revenue from FYB201 was realized through the 50% at-equity investment in Bioeq AG. The at-equity result is not included in revenue and is reported below EBITDA (see below).

Group EBITDA for the first three months amounted to €-13.2 million (Q1/2024: €-5.5 million), primarily reflecting the aforementioned decline in revenues. However, the initial revenue contribution from FYB202/Otulfi^® is viewed positively. The Stelara^® biosimilar was launched at the end of the first quarter in the U.S. and Europe and remains in the early stage of market ramp-up. Increasing research and development expenses related to early-stage biosimilar candidates also impacted Group EBITDA accordingly.

Adjusted Group EBITDA amounted to €-11.8 million (Q1/2024: €2.9 million) and was in line with expectations. The result was primarily attributable to the weaker performance of FYB201 in the U.S. and the resulting lower earnings contribution from Bioeq AG (at-equity result), which amounted to €1.4 million (Q1/2024: €4.3 million).

Working capital as of March 31, 2025, stood at €29.4 million (December 31, 2024: €55.1 million). The year-over-year change reflects initial investment savings in FYB206, where development costs are capitalized and thus cash-effective but not EBITDA-relevant. The existing shareholder loan of €48.0 million remains fully available and can be drawn flexibly.

Formycon confirms its full-year 2025 guidance and continues to pursue sustainable and EBITDA-positive development. Management still anticipates achieving positive EBITDA as early as 2026, but no later than 2027.

Key financial figures at a glance (in € million):

Conference call and webcast

The Executive Management Board of Formycon AG will discuss the company’s development and key financial figures during a conference call. The earnings call, which will be webcast live, will take place today, May 12, 2025, at 3:00 p.m. (CEST) in English.

To participate in the conference call, please register at:

https://webcast.meetyoo.de/reg/dv2D4A5Z3vhL

After registering, participants will receive a confirmation email with individual dial-in details and the date.

The presentation and audio broadcast can be accessed via the following webcast link:

https://www.webcast-eqs.com/formycon-2025-q1

Following a short presentation, the Executive Board will be available to answer analysts’ questions. The webcast will be recorded and will be available to view afterwards on the Formycon website at https://www.formycon.com/en/investor-relations/publications/

¹⁾ Otulfi^® is a registered trademark of Fresenius Kabi Deutschland GmbH in selected countries
²⁾ Stelara^® is a registered trademark of Johnson & Johnson
³⁾ Eylea^® is a registered trademark of Regeneron Pharmaceuticals Inc.
⁴⁾ Keytruda^® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co, Inc, Rahway, NJ/USA
⁵⁾ AHZANTIVE^® is a registered trademark of Klinge Biopharma GmbH
⁶⁾ Baiama^® is a registered trademark of Klinge Biopharma GmbH
⁷⁾ EMA Reflection Paper  www.ema.europa.eu/en/reflection-paper-tailored-clinical-approach-biosimilar-development
⁸⁾ CIMERLI^® is a registered trademark of Coherus BioSciences, Inc.
⁹⁾ Lucentis^® is a registered trademark of Genentech Inc.

Planegg-Martinsried, Germany – Formycon AG (FSB: FYB, Prime Standard, „Formycon“) plans to publish its results for the first quarter of 2025 on May 12, 2025. The Management Board will discuss the company’s development, key financial figures, and provide an outlook for the course of 2025. The conference call, which will be broadcast live on the internet, will take place on May 12, 2025, at 3:00 PM (CEST) in English.

To participate in the conference call, please register at:
https://webcast.meetyoo.de/reg/dv2D4A5Z3vhL

After registration, participants will receive a confirmation email with individual dial-in data.

The presentation and audio broadcast can be accessed via the following webcast link:
https://www.webcast-eqs.com/formycon-2025-q1

After a brief presentation, the Management Board will be available for analysts’ questions. The conference call will be recorded and can subsequently be accessed via the Formycon website at: https://www.formycon.com/en/investor-relations/publications/

Formycon in Dialogue

Additionally, representatives of the Management Board will participate in the following international investor conferences in the coming weeks:

May 13 – May 14, 2025
Equity Forum Spring Conference
Dr. Stefan Glombitza (CEO)
Frankfurt

May 21 – May 22, 2025
Berenberg European Conference
Enno Spillner (CFO)
New York

June 11, 2025
UBS Life Science Conference 2025
Enno Spillner (CFO)
London

June 12, 2025
Warburg Highlights Conference
Enno Spillner (CFO)
Hamburg

August 28, 2025
Hamburg Investors’ Days (HIT)
Enno Spillner (CFO)
Hamburg

September 8 – 10, 2025
H.C. Wainwright 27th Annual Global Investment Conference
Enno Spillner (CFO)
New York

September 22, 2025
Berenberg & Goldman Sachs German Corporate Conference
Dr. Stefan Glombitza (CEO), Enno Spillner (CFO)
Munich

Please find our current events at:
https://www.formycon.com/en/investors/financial-calendar/